Awards & Advancement

INC Research adds James Featherstone, Janet Baldwin, Nathalie Doize & Alastair MacDonald to team

Friday, March 31, 2017

INC Research Holdings, a global phase I to IV CRO, has appointed several new senior leaders to strengthen its Real World & Late Phase (RWLP) and Global Consulting offerings to biopharmaceutical customers worldwide. INC’s RWLP team is dedicated to real world, evidence-based data collection and works in close collaboration with the Company’s Global Consulting business to support customers at every stage of their product and portfolio development. INC’s expanded team will help maximize value for sponsors throughout the product lifecycle, from concept to commercialization, by providing consultative and operational expertise in the delivery of real-world evidence. The appointments reinforce INC’s continued focus on providing customers with strategic consulting services along with the right evidence to make the best clinical decisions in this rapidly expanding segment of the clinical research environment.

[Read More]

Bridge Medicines appoints William J. Polvino chief executive officer

Tuesday, March 28, 2017

Bridge Medicines, a drug discovery company focused on advancing promising early technologies from concept to clinic, announced the appointment of William J. Polvino, M.D., as chief executive officer (CEO). In conjunction, Kathleen Metters, Ph.D., who served as the interim CEO upon the establishment of Bridge Medicines in October 2016, will continue to have an operating role within Bridge Medicines, and will Chair the Scientific Advisory Board.

[Read More]

Alexion appoints Ludwig Hantson chief executive officer

Tuesday, March 28, 2017

Alexion Pharmaceuticals announced that its board of directors has appointed Ludwig N. Hantson, Ph.D., as chief executive officer and member of the board of directors, effective immediately. Dr. Hantson most recently served as president and CEO of Baxalta, a spin-off as a public company from Baxter, and a developer of therapies for orphan and underserved diseases in hematology, immunology and oncology. Dr. Hantson brings to Alexion a strong record of developing diverse rare disease pipelines and commercializing innovative and life-transformative therapies at industry-leading companies.

[Read More]

Woody Sherman joins Silicon Therapeutics as chief scientific officer

Monday, March 27, 2017

Silicon Therapeutics (Silicon Tx), an integrated computational drug discovery company creating novel small molecule therapeutics for difficult to target proteins, has announced the appointment of Woody Sherman Ph.D., as chief scientific officer to lead the development and application of its INSITE platform as STX continues its trajectory toward being the first truly integrated computational drug discovery company with massive physics-based simulations tightly integrated within their drug discovery and design workflows.

[Read More]

DrugDev hits record milestone of over $2B processed to sites

Monday, March 20, 2017

Sponsors and CROs worldwide have elevated DrugDev to an industry milestone of over $2 billion in aggregate payments to clinical investigator sites—an accomplishment unequaled by any other provider, including all but the very largest CROs. Over the past 10 years that experience amounts to more than 26,000 site recipients in 60 countries on more than 1,800 clinical trials.

[Read More]